LOGIN
ID
PW
MemberShip
2023-09-24 04:58
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Boryung develops 4-drug kanarb combo¡¦ increases lineup
by
Chon, Seung-Hyun
Sep 22, 2023 05:42am
On the 20th, Boryung Pharmaceutical announced that the Ministry of Food and Drug Safety has approved the Phase III clinical trial plan (investigational new drug, IND) for ¡®BR1018,¡¯ its incrementally modified drug candidate for hypertension and dyslipidemia. BR1018 is a four-drug combination that combined amlodipine, atorvastatin, and e
Company
Next-gen asthma drug Tezspire to soon be introduced to KOR
by
Eo, Yun-Ho
Sep 22, 2023 05:41am
The next-generation drug for severe asthma, ¡®Tezpire' is soon expected to enter the Korean market. According to industry sources, AstraZeneca Korea has submitted an application for the approval of ¡®Tezspire (tezepelumab)¡¯ in H2 to the Ministry of Food and Drug Safety and is receiving its final review. Whether AstraZeneca will be abl
Company
A new drug for optic shylomyelitis is necessary
by
Eo, Yun-Ho
Sep 20, 2023 05:35am
Off labels refer to the act of prescribing a medicine for an indication other than a use approved by the Ministry of Food and Drug Safety. In general, the use of the drug has been determined by the health authorities, and the question may arise as to why it is necessary. However, there is an area of disease where this Off label prescri
Company
Pricing & reimbursement specialist introduced as a new job
by
Kang, Shin-Kook
Sep 20, 2023 05:35am
New occupations such as ¡®Pricing & reimbursement specialist¡¯ and ¡®biopharmaceutical candidate substance researcher¡¯ were added as new occupations in the bio and pharmaceutical industry. On the 19th, the Korea Employment Information Service (President Young-Jun Kim) announced it had added 156 new occupations in the fields of life scien
Company
No news after passing the cancer screening
by
Eo, Yun-Ho
Sep 20, 2023 05:35am
Xospata's progress in expanding insurance benefits, which seemed to be going smoothly, appears to have stopped. According to related industries, Astellas Korea Pharmaceutical's FLT3 mutation-positive recurrence or Acute Myeloid Leukemia treatment Xospata was not submitted during the three HIRA Pharmaceutical Reimbursement Evaluation Commi
Company
Korea United Pharm signs export agreement with Vietnam TAK
by
Nho, Byung Chul
Sep 19, 2023 05:42am
On the 18th, Korea United Pharm (CEO Duk-Young Kang) attended the 2023 Global Bio& Pharma Plaza (GBPP) 2023 and forged close relationships with over 20 overseas buyers. The company announced that it had accelerated its global expansion by signing export contracts for Vietnam and the Philippines on the day of the event. Korea United Phar
Company
nAMD drug Vabysmo will likely be listed for reimb in Oct
by
Eo, Yun-Ho
Sep 18, 2023 05:26am
The macular degeneration treatment ¡®Vabysmo¡¯ is expected to be listed for reimbursement in October this year. According to industry sources, Roche Korea has completed drug pricing negotiations for its bispecific antibody Vabysmo (faricimab) with the National Health Insurance Service. Once it passes the Health Insurance Policy Review Com
Company
KRW 100 bil loxoprofen market suffers reimb cuts
by
Chon, Seung-Hyun
Sep 18, 2023 05:26am
Industry concerns are rising on the announcement of reimbursement cuts for the nonsteroidal anti-inflammatory drug ¡®loxoprofen.¡¯ The adequacy of its reimbursement as an antipyretic/analgesic for acute upper respiratory tract inflammation has not been recognized by the authorities in Korea, and its scope of prescriptions is set to be narrowed a
Company
nAMD tx Vabysmo can be prescribed at general hospitals
by
Eo, Yun-Ho
Sep 15, 2023 05:33am
Vabysmo, a treatment for macular degeneration, can be prescribed at general hospitals. According to related industries, Vabysmo, Roche Korea's first bispecific antibody treatment for eye diseases, passed the drug committee of medical institutions such as Konyang University Hospital, Kim Eye Clinic, Nune Eye Clinic, Inje University Busan P
Company
Gilead Sciences Korea appoints Jae-Yeon Choi as new head
by
Eo, Yun-Ho
Sep 15, 2023 05:33am
Gilead Sciences Korea announced it has appointed Jae-Yeon Choi as its new General Manager as of October this year. The position had remained vacant for the past 6 months. At Gilead Sciences Korea, the new GM Choi will oversee Gilead's business operations in Korea, and promote businesses in the fields of HIV, viral hepatitis, COVID-19, an
1
2
3
4
5
6
7
8
9
10
>